aluates Reports

$ 0.0

Automative

Global Oral Antituberculosis Drugs Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-18L8554

Global Oral Antituberculosis Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Global Oral Antituberculosis Drugs Market Research Report 2025

Code: QYRE-Auto-18L8554

Report

July 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Lupin Ltd

Macleods Pharmaceuticals

Otsuka Pharmaceutical

Johnson & Johnson

Pfizer Inc

Novartis

Abbott

Astrazeneca plc

Bayer

Eli Lilly

GlaxoSmithKline PLC

Merck

Sanofi

Chongqing Huapont Pharm

Shuangding Pharm

Hongqi pharmaceutical

Oral Antituberculosis Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Oral Antituberculosis Drugs Market

The global market for Oral Antituberculosis Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Oral Antituberculosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Antituberculosis Drugs.

The Oral Antituberculosis Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oral Antituberculosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Antituberculosis Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Oral Antituberculosis Drugs Market Report

Report Metric	Details
Report Name	Oral Antituberculosis Drugs Market
CAGR	5%
Segment by Type	Isoniazid Rifampin Ethambutol Pyrazinamide Otherr
Segment by Application	Hospitals and Clinics Government Agencies Non-Profit Organizations Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Chongqing Huapont Pharm, Shuangding Pharm, Hongqi pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Antituberculosis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Oral Antituberculosis Drugs Market report?

Ans: The main players in the Oral Antituberculosis Drugs Market are Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi, Chongqing Huapont Pharm, Shuangding Pharm, Hongqi pharmaceutical

What are the Application segmentation covered in the Oral Antituberculosis Drugs Market report?

Ans: The Applications covered in the Oral Antituberculosis Drugs Market report are Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others

What are the Type segmentation covered in the Oral Antituberculosis Drugs Market report?

Ans: The Types covered in the Oral Antituberculosis Drugs Market report are Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr

Recommended Reports

Oral Pharmaceuticals

Infectious Disease Drugs

Chronic Disease Treatments

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oral Antituberculosis Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Isoniazid

1.2.3 Rifampin

1.2.4 Ethambutol

1.2.5 Pyrazinamide

1.2.6 Otherr

1.3 Market by Application

1.3.1 Global Oral Antituberculosis Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals and Clinics

1.3.3 Government Agencies

1.3.4 Non-Profit Organizations

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oral Antituberculosis Drugs Market Perspective (2020-2031)

2.2 Global Oral Antituberculosis Drugs Growth Trends by Region

2.2.1 Global Oral Antituberculosis Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Oral Antituberculosis Drugs Historic Market Size by Region (2020-2025)

2.2.3 Oral Antituberculosis Drugs Forecasted Market Size by Region (2026-2031)

2.3 Oral Antituberculosis Drugs Market Dynamics

2.3.1 Oral Antituberculosis Drugs Industry Trends

2.3.2 Oral Antituberculosis Drugs Market Drivers

2.3.3 Oral Antituberculosis Drugs Market Challenges

2.3.4 Oral Antituberculosis Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oral Antituberculosis Drugs Players by Revenue

3.1.1 Global Top Oral Antituberculosis Drugs Players by Revenue (2020-2025)

3.1.2 Global Oral Antituberculosis Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Oral Antituberculosis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Oral Antituberculosis Drugs Revenue

3.4 Global Oral Antituberculosis Drugs Market Concentration Ratio

3.4.1 Global Oral Antituberculosis Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oral Antituberculosis Drugs Revenue in 2024

3.5 Global Key Players of Oral Antituberculosis Drugs Head office and Area Served

3.6 Global Key Players of Oral Antituberculosis Drugs, Product and Application

3.7 Global Key Players of Oral Antituberculosis Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Oral Antituberculosis Drugs Breakdown Data by Type

4.1 Global Oral Antituberculosis Drugs Historic Market Size by Type (2020-2025)

4.2 Global Oral Antituberculosis Drugs Forecasted Market Size by Type (2026-2031)

5 Oral Antituberculosis Drugs Breakdown Data by Application

5.1 Global Oral Antituberculosis Drugs Historic Market Size by Application (2020-2025)

5.2 Global Oral Antituberculosis Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Oral Antituberculosis Drugs Market Size (2020-2031)

6.2 North America Oral Antituberculosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Oral Antituberculosis Drugs Market Size by Country (2020-2025)

6.4 North America Oral Antituberculosis Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oral Antituberculosis Drugs Market Size (2020-2031)

7.2 Europe Oral Antituberculosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Oral Antituberculosis Drugs Market Size by Country (2020-2025)

7.4 Europe Oral Antituberculosis Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Oral Antituberculosis Drugs Market Size (2020-2031)

8.2 Asia-Pacific Oral Antituberculosis Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Oral Antituberculosis Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Oral Antituberculosis Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Oral Antituberculosis Drugs Market Size (2020-2031)

9.2 Latin America Oral Antituberculosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Oral Antituberculosis Drugs Market Size by Country (2020-2025)

9.4 Latin America Oral Antituberculosis Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oral Antituberculosis Drugs Market Size (2020-2031)

10.2 Middle East & Africa Oral Antituberculosis Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Oral Antituberculosis Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Oral Antituberculosis Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lupin

11.1.1 Lupin Company Details

11.1.2 Lupin Business Overview

11.1.3 Lupin Oral Antituberculosis Drugs Introduction

11.1.4 Lupin Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.1.5 Lupin Recent Development

11.2 Macleods Pharmaceuticals

11.2.1 Macleods Pharmaceuticals Company Details

11.2.2 Macleods Pharmaceuticals Business Overview

11.2.3 Macleods Pharmaceuticals Oral Antituberculosis Drugs Introduction

11.2.4 Macleods Pharmaceuticals Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.2.5 Macleods Pharmaceuticals Recent Development

11.3 Otsuka Pharmaceutical

11.3.1 Otsuka Pharmaceutical Company Details

11.3.2 Otsuka Pharmaceutical Business Overview

11.3.3 Otsuka Pharmaceutical Oral Antituberculosis Drugs Introduction

11.3.4 Otsuka Pharmaceutical Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.3.5 Otsuka Pharmaceutical Recent Development

11.4 Johnson & Johnson

11.4.1 Johnson & Johnson Company Details

11.4.2 Johnson & Johnson Business Overview

11.4.3 Johnson & Johnson Oral Antituberculosis Drugs Introduction

11.4.4 Johnson & Johnson Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.4.5 Johnson & Johnson Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Oral Antituberculosis Drugs Introduction

11.5.4 Pfizer Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Novartis

11.6.1 Novartis Company Details

11.6.2 Novartis Business Overview

11.6.3 Novartis Oral Antituberculosis Drugs Introduction

11.6.4 Novartis Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.6.5 Novartis Recent Development

11.7 Abbott

11.7.1 Abbott Company Details

11.7.2 Abbott Business Overview

11.7.3 Abbott Oral Antituberculosis Drugs Introduction

11.7.4 Abbott Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.7.5 Abbott Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Oral Antituberculosis Drugs Introduction

11.8.4 AstraZeneca Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Bayer

11.9.1 Bayer Company Details

11.9.2 Bayer Business Overview

11.9.3 Bayer Oral Antituberculosis Drugs Introduction

11.9.4 Bayer Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.9.5 Bayer Recent Development

11.10 Eli Lilly

11.10.1 Eli Lilly Company Details

11.10.2 Eli Lilly Business Overview

11.10.3 Eli Lilly Oral Antituberculosis Drugs Introduction

11.10.4 Eli Lilly Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.10.5 Eli Lilly Recent Development

11.11 GlaxoSmithKline

11.11.1 GlaxoSmithKline Company Details

11.11.2 GlaxoSmithKline Business Overview

11.11.3 GlaxoSmithKline Oral Antituberculosis Drugs Introduction

11.11.4 GlaxoSmithKline Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.11.5 GlaxoSmithKline Recent Development

11.12 Merck

11.12.1 Merck Company Details

11.12.2 Merck Business Overview

11.12.3 Merck Oral Antituberculosis Drugs Introduction

11.12.4 Merck Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.12.5 Merck Recent Development

11.13 Sanofi

11.13.1 Sanofi Company Details

11.13.2 Sanofi Business Overview

11.13.3 Sanofi Oral Antituberculosis Drugs Introduction

11.13.4 Sanofi Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.13.5 Sanofi Recent Development

11.14 Chongqing Huapont Pharm

11.14.1 Chongqing Huapont Pharm Company Details

11.14.2 Chongqing Huapont Pharm Business Overview

11.14.3 Chongqing Huapont Pharm Oral Antituberculosis Drugs Introduction

11.14.4 Chongqing Huapont Pharm Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.14.5 Chongqing Huapont Pharm Recent Development

11.15 Shuangding Pharm

11.15.1 Shuangding Pharm Company Details

11.15.2 Shuangding Pharm Business Overview

11.15.3 Shuangding Pharm Oral Antituberculosis Drugs Introduction

11.15.4 Shuangding Pharm Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.15.5 Shuangding Pharm Recent Development

11.16 Hongqi pharmaceutical

11.16.1 Hongqi pharmaceutical Company Details

11.16.2 Hongqi pharmaceutical Business Overview

11.16.3 Hongqi pharmaceutical Oral Antituberculosis Drugs Introduction

11.16.4 Hongqi pharmaceutical Revenue in Oral Antituberculosis Drugs Business (2020-2025)

11.16.5 Hongqi pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lupin Ltd

Macleods Pharmaceuticals

Otsuka Pharmaceutical

Johnson & Johnson

Pfizer Inc

Novartis

Abbott

Astrazeneca plc

Bayer

Eli Lilly

GlaxoSmithKline PLC

Merck

Sanofi

Chongqing Huapont Pharm

Shuangding Pharm

Hongqi pharmaceutical

List of Tables

Table 1. Global Oral Antituberculosis Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Isoniazid

Table 3. Key Players of Rifampin

Table 4. Key Players of Ethambutol

Table 5. Key Players of Pyrazinamide

Table 6. Key Players of Otherr

Table 7. Global Oral Antituberculosis Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Oral Antituberculosis Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Oral Antituberculosis Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Oral Antituberculosis Drugs Market Share by Region (2020-2025)

Table 11. Global Oral Antituberculosis Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Oral Antituberculosis Drugs Market Share by Region (2026-2031)

Table 13. Oral Antituberculosis Drugs Market Trends

Table 14. Oral Antituberculosis Drugs Market Drivers

Table 15. Oral Antituberculosis Drugs Market Challenges

Table 16. Oral Antituberculosis Drugs Market Restraints

Table 17. Global Oral Antituberculosis Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Oral Antituberculosis Drugs Market Share by Players (2020-2025)

Table 19. Global Top Oral Antituberculosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Antituberculosis Drugs as of 2024)

Table 20. Ranking of Global Top Oral Antituberculosis Drugs Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Oral Antituberculosis Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Oral Antituberculosis Drugs, Headquarters and Area Served

Table 23. Global Key Players of Oral Antituberculosis Drugs, Product and Application

Table 24. Global Key Players of Oral Antituberculosis Drugs, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Oral Antituberculosis Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Oral Antituberculosis Drugs Revenue Market Share by Type (2020-2025)

Table 28. Global Oral Antituberculosis Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Oral Antituberculosis Drugs Revenue Market Share by Type (2026-2031)

Table 30. Global Oral Antituberculosis Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Oral Antituberculosis Drugs Revenue Market Share by Application (2020-2025)

Table 32. Global Oral Antituberculosis Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Oral Antituberculosis Drugs Revenue Market Share by Application (2026-2031)

Table 34. North America Oral Antituberculosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Oral Antituberculosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Oral Antituberculosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Oral Antituberculosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Oral Antituberculosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Oral Antituberculosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Oral Antituberculosis Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Oral Antituberculosis Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Oral Antituberculosis Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Oral Antituberculosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Oral Antituberculosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Oral Antituberculosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Oral Antituberculosis Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Oral Antituberculosis Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Oral Antituberculosis Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 49. Lupin Company Details

Table 50. Lupin Business Overview

Table 51. Lupin Oral Antituberculosis Drugs Product

Table 52. Lupin Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 53. Lupin Recent Development

Table 54. Macleods Pharmaceuticals Company Details

Table 55. Macleods Pharmaceuticals Business Overview

Table 56. Macleods Pharmaceuticals Oral Antituberculosis Drugs Product

Table 57. Macleods Pharmaceuticals Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 58. Macleods Pharmaceuticals Recent Development

Table 59. Otsuka Pharmaceutical Company Details

Table 60. Otsuka Pharmaceutical Business Overview

Table 61. Otsuka Pharmaceutical Oral Antituberculosis Drugs Product

Table 62. Otsuka Pharmaceutical Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 63. Otsuka Pharmaceutical Recent Development

Table 64. Johnson & Johnson Company Details

Table 65. Johnson & Johnson Business Overview

Table 66. Johnson & Johnson Oral Antituberculosis Drugs Product

Table 67. Johnson & Johnson Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 68. Johnson & Johnson Recent Development

Table 69. Pfizer Company Details

Table 70. Pfizer Business Overview

Table 71. Pfizer Oral Antituberculosis Drugs Product

Table 72. Pfizer Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 73. Pfizer Recent Development

Table 74. Novartis Company Details

Table 75. Novartis Business Overview

Table 76. Novartis Oral Antituberculosis Drugs Product

Table 77. Novartis Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 78. Novartis Recent Development

Table 79. Abbott Company Details

Table 80. Abbott Business Overview

Table 81. Abbott Oral Antituberculosis Drugs Product

Table 82. Abbott Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 83. Abbott Recent Development

Table 84. AstraZeneca Company Details

Table 85. AstraZeneca Business Overview

Table 86. AstraZeneca Oral Antituberculosis Drugs Product

Table 87. AstraZeneca Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 88. AstraZeneca Recent Development

Table 89. Bayer Company Details

Table 90. Bayer Business Overview

Table 91. Bayer Oral Antituberculosis Drugs Product

Table 92. Bayer Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 93. Bayer Recent Development

Table 94. Eli Lilly Company Details

Table 95. Eli Lilly Business Overview

Table 96. Eli Lilly Oral Antituberculosis Drugs Product

Table 97. Eli Lilly Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 98. Eli Lilly Recent Development

Table 99. GlaxoSmithKline Company Details

Table 100. GlaxoSmithKline Business Overview

Table 101. GlaxoSmithKline Oral Antituberculosis Drugs Product

Table 102. GlaxoSmithKline Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 103. GlaxoSmithKline Recent Development

Table 104. Merck Company Details

Table 105. Merck Business Overview

Table 106. Merck Oral Antituberculosis Drugs Product

Table 107. Merck Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 108. Merck Recent Development

Table 109. Sanofi Company Details

Table 110. Sanofi Business Overview

Table 111. Sanofi Oral Antituberculosis Drugs Product

Table 112. Sanofi Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 113. Sanofi Recent Development

Table 114. Chongqing Huapont Pharm Company Details

Table 115. Chongqing Huapont Pharm Business Overview

Table 116. Chongqing Huapont Pharm Oral Antituberculosis Drugs Product

Table 117. Chongqing Huapont Pharm Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 118. Chongqing Huapont Pharm Recent Development

Table 119. Shuangding Pharm Company Details

Table 120. Shuangding Pharm Business Overview

Table 121. Shuangding Pharm Oral Antituberculosis Drugs Product

Table 122. Shuangding Pharm Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 123. Shuangding Pharm Recent Development

Table 124. Hongqi pharmaceutical Company Details

Table 125. Hongqi pharmaceutical Business Overview

Table 126. Hongqi pharmaceutical Oral Antituberculosis Drugs Product

Table 127. Hongqi pharmaceutical Revenue in Oral Antituberculosis Drugs Business (2020-2025) & (US$ Million)

Table 128. Hongqi pharmaceutical Recent Development

Table 129. Research Programs/Design for This Report

Table 130. Key Data Information from Secondary Sources

Table 131. Key Data Information from Primary Sources

Table 132. Authors List of This Report

List of Figures

Figure 1. Oral Antituberculosis Drugs Picture

Figure 2. Global Oral Antituberculosis Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Oral Antituberculosis Drugs Market Share by Type: 2024 VS 2031

Figure 4. Isoniazid Features

Figure 5. Rifampin Features

Figure 6. Ethambutol Features

Figure 7. Pyrazinamide Features

Figure 8. Otherr Features

Figure 9. Global Oral Antituberculosis Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Oral Antituberculosis Drugs Market Share by Application: 2024 VS 2031

Figure 11. Hospitals and Clinics Case Studies

Figure 12. Government Agencies Case Studies

Figure 13. Non-Profit Organizations Case Studies

Figure 14. Others Case Studies

Figure 15. Oral Antituberculosis Drugs Report Years Considered

Figure 16. Global Oral Antituberculosis Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global Oral Antituberculosis Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global Oral Antituberculosis Drugs Market Share by Region: 2024 VS 2031

Figure 19. Global Oral Antituberculosis Drugs Market Share by Players in 2024

Figure 20. Global Top Oral Antituberculosis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Antituberculosis Drugs as of 2024)

Figure 21. The Top 10 and 5 Players Market Share by Oral Antituberculosis Drugs Revenue in 2024

Figure 22. North America Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America Oral Antituberculosis Drugs Market Share by Country (2020-2031)

Figure 24. United States Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Oral Antituberculosis Drugs Market Share by Country (2020-2031)

Figure 28. Germany Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Oral Antituberculosis Drugs Market Share by Region (2020-2031)

Figure 36. China Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Oral Antituberculosis Drugs Market Share by Country (2020-2031)

Figure 44. Mexico Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Oral Antituberculosis Drugs Market Share by Country (2020-2031)

Figure 48. Turkey Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE Oral Antituberculosis Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Lupin Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 52. Macleods Pharmaceuticals Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 53. Otsuka Pharmaceutical Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 54. Johnson & Johnson Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 55. Pfizer Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 56. Novartis Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 57. Abbott Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 58. AstraZeneca Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 59. Bayer Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 60. Eli Lilly Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 61. GlaxoSmithKline Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 62. Merck Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 63. Sanofi Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 64. Chongqing Huapont Pharm Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 65. Shuangding Pharm Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 66. Hongqi pharmaceutical Revenue Growth Rate in Oral Antituberculosis Drugs Business (2020-2025)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Mycobacterium Tuberculosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Active Tuberculosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Mycobacterium Tuberculosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Tuberculosis Vaccine Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oral Anti allergic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nontuberculous Mycobacterium Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oral Rabies Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oral Diuretic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Antiviral Medicine Market Research Report 2025

Global Oral Antifungal Drugs Market Insights Forecast to 2030

Global Oral Antifungals Market Insights Forecast to 2030

Generic Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral Antifungal Medication Market Insights Forecast to 2030

Global Anti infectious Disease Drugs Market Research Report 2025

Global Human Tuberculosis Vaccine Market Research Report 2025

Oral Drug Packaging Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oral Bordetella Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oral COVID 19 Drug Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions